Latest Diabetes management Stories

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) for an investigational SGLT-2 inhibitor, empagliflozin, at the 48(th) European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin. The new analysis showed a reduction in systolic blood pressure with empagliflozin,...

OAKLAND, Calif., Oct. 1, 2012 /PRNewswire/ -- Use of electronic health records was associated with improved drug-treatment intensification, monitoring and risk-factor control among patients with diabetes, according to a new Kaiser Permanente study. In the study, which appears in the current issue of Annals of Internal Medicine, researchers also noted greater improvements among patients with poorer control of their diabetes and lipids. The findings provide an important contribution...

Extending sleep duration may help to reduce diabetes risk in youth A new study suggests that increasing the amount of sleep that teenagers get could improve their insulin resistance and prevent the future onset of diabetes. "High levels of insulin resistance can lead to the development of diabetes," said lead author Karen Matthews, PhD, of the University of Pittsburgh Department of Psychiatry. "We found that if teens that normally get six hours of sleep per night get one extra hour of...

INDIANAPOLIS, Oct. 1, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK Combo system for insulin pump therapy is now available in the United States. This market launch follows clearance from the U.S. Food and Drug Administration (FDA) for the ACCU-CHEK Combo system in July 2012. People with diabetes who are interested in learning more about the system should contact Roche Insulin Delivery Services at 1-866-382-2355. (Photo:...

DENVER, Oct. 1, 2012 /PRNewswire/ -- The World Health Organization estimates that approximately 347 million people worldwide have diabetes and this figure is expected to increase by two thirds by 2030. A new international study published in the October issue of the medical journal Nutrition, compared low-carb with low-calorie diets in obese and diabetic patients and found that a low-carb approach, such as the Atkins Diet((TM)), can assist in reversing this global trend. The study...

HORW, Switzerland, Sept. 26, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ(® )Insulin Delivery Device. The study was designed to evaluate the ability of people with type 2 diabetes to use PaQ in replacing their multiple daily insulin injections required to control their blood sugar. Study endpoints included glycemic control, patient...

NEW BRUNSWICK, N.J., Sept. 26, 2012 /PRNewswire-FirstCall/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany. First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in...

RARITAN, N.J., Sept. 25, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) will present new Phase 3 data results evaluating canagliflozin, an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, in adult patients with type 2 diabetes at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD), from October 1-5, 2012 in Berlin, Germany. "The data we will present at EASD are the latest results from our...

ABINGDON, England, September 25, 2012 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, will update the industry on its progress toward U.S. and European regulatory trials at two leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit Europe on November 14 in Dublin. Tight Glycemic Control (TGC) in...

PITTSBURGH, Sept. 21, 2012 /PRNewswire/ -- Highmark Inc. and Healthrageous, Inc., a digital health management company, announced today they are evaluating a lifestyle behavior modification program to improve the health status of people with Type 2 diabetes. The goal of the program is to use technology in a way that makes the personalized journey of self-managing diabetes easier and more effective. Healthrageous' digital diabetes program takes into account an individual's needs and...